Autolus Therapeutics (NASDAQ:AUTL) Downgraded to Strong Sell Rating by Zacks Research

Autolus Therapeutics (NASDAQ:AUTL) was downgraded by analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a note issued to investors on Wednesday,Zacks.com reports.

Several other equities research analysts also recently issued reports on AUTL. Weiss Ratings reiterated a “sell (d-)” rating on shares of Autolus Therapeutics in a research note on Wednesday. Needham & Company LLC dropped their price target on Autolus Therapeutics from $11.00 to $10.00 and set a “buy” rating on the stock in a research report on Monday, January 12th. Wall Street Zen downgraded Autolus Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Saturday, November 15th. Finally, William Blair restated an “outperform” rating on shares of Autolus Therapeutics in a research note on Wednesday, September 24th. Four research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Autolus Therapeutics has an average rating of “Hold” and a consensus target price of $8.33.

Autolus Therapeutics Stock Up 3.4%

Autolus Therapeutics stock opened at $1.52 on Wednesday. Autolus Therapeutics has a 52 week low of $1.11 and a 52 week high of $2.70. The firm has a market capitalization of $404.53 million, a PE ratio of -1.83 and a beta of 2.01. The firm’s 50-day simple moving average is $1.56 and its 200 day simple moving average is $1.72.

Autolus Therapeutics (NASDAQ:AUTL) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.07). The firm had revenue of $21.19 million for the quarter, compared to analysts’ expectations of $21.08 million. Autolus Therapeutics had a negative return on equity of 63.76% and a negative net margin of 439.69%. On average, research analysts expect that Autolus Therapeutics will post -0.94 EPS for the current fiscal year.

Institutional Trading of Autolus Therapeutics

Institutional investors have recently made changes to their positions in the stock. Marex Group plc purchased a new stake in Autolus Therapeutics in the 2nd quarter worth approximately $28,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Autolus Therapeutics during the 3rd quarter worth about $46,000. R Squared Ltd acquired a new position in Autolus Therapeutics in the second quarter worth approximately $50,000. Invesco Ltd. grew its position in Autolus Therapeutics by 53.3% in the first quarter. Invesco Ltd. now owns 32,738 shares of the company’s stock worth $51,000 after acquiring an additional 11,381 shares in the last quarter. Finally, Delaney Dennis R bought a new stake in Autolus Therapeutics in the second quarter worth $55,000. 72.83% of the stock is currently owned by institutional investors and hedge funds.

Autolus Therapeutics Company Profile

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.